Primmune Therapeutics Enrolled Second Study Patient
The company reached a key milestone in its Phase 2 clinical trial testing a novel melanoma treatment regimen.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you believe experimental immunotherapy combinations are worth the risk for early-stage cancer patients?
Primmune Therapeutics has enrolled the second patient in its Phase 2 INFLECTION-003 clinical study. The trial is testing the efficacy of polvitolimod HCl combined with pembrolizumab for patients with resectable stage III melanoma.
Why it matters
The study aims to determine if this neoadjuvant therapy combination can increase major pathologic response rates for patients before they undergo surgical resection. This milestone also triggered the release of the second tranche of corporate financing.
The INFLECTION-003 study is a Phase 2 trial utilizing an oral TLR7/IRF7 agonist administered for 9 weeks. Preliminary safety data from two Phase 1 studies involved 118 healthy volunteers with no serious adverse events reported.
The players
Primmune Therapeutics
This is a biopharmaceutical company focused on developing novel oral small-molecule TLR7/IRF7 agonists for the treatment of cancer.
The details
Participants receive oral polvitolimod HCl alongside intravenous pembrolizumab for a 9-week period prior to surgery. The research team intends to measure how this regimen influences surgical outcomes for those diagnosed with stage III melanoma.
Timeline
September 24, 2026: Enrollment of the second patient occurred.
The Big Picture
This study follows the established pattern of current neoadjuvant immunotherapy clinical research frameworks by evaluating treatment responses prior to surgery.
Patients with resectable stage III melanoma may eventually have access to new neoadjuvant options if this drug combination proves effective in trials. Currently, the treatment is strictly limited to participants enrolled in the controlled clinical study.
The takeaway
Clinical trials for melanoma are shifting toward earlier, neoadjuvant interventions to improve long-term surgical success. Interested patients should consult with their oncologists to determine if they meet the specific criteria for current or upcoming clinical research.
Further reading
Learn more about ongoing developments in this field at the Cancer section.
More information
Review the full clinical study information portal for additional details on the trial design.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe experimental immunotherapy combinations are worth the risk for early-stage cancer patients?
